Evidence map›Paper›PMID 42274613›Full record

ArticleCells2026

Generation of Heterotypic Primary Human Spheroids from Glioblastoma Resections and (Pre-)Clinical Applications.

Sophia Elisa Wiener, Jens Conrad, Saman Javid, Sophie Gieß, Max Jägersberg, Harald Krenzlin, Naureen Keric, Anne Régnier-Vigouroux, Carsten Geiß

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sophia Elisa WienerInstitute for Developmental Biology and Neurobiology, Johannes Gutenberg University, 55128 Mainz, Germany.
Jens ConradDepartment of Neurosurgery, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-5138-9293
Saman JavidInstitute for Developmental Biology and Neurobiology, Johannes Gutenberg University, 55128 Mainz, Germany.
Sophie GießInstitute for Developmental Biology and Neurobiology, Johannes Gutenberg University, 55128 Mainz, Germany.
Max JägersbergDepartment of Neurosurgery, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Harald KrenzlinDepartment of Neurosurgery, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Naureen KericDepartment of Neurosurgery, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Anne Régnier-VigourouxInstitute for Developmental Biology and Neurobiology, Johannes Gutenberg University, 55128 Mainz, Germany.
Carsten GeißInstitute for Developmental Biology and Neurobiology, Johannes Gutenberg University, 55128 Mainz, Germany.ORCID 0000-0001-9572-2476

Funding

Johannes Gutenberg University Mainz inneruniversitäre Forschungsförderung
6 · The paper itself

Abstract

The rapid expansion of individualized treatment strategies necessitates advanced patient-specific screening platforms recapitulating tumor complexity. Here, we present such a platform preserving heterotypic cellular interactions and three-dimensional architecture which are both critical for predicting therapeutic responses. This cost-effective and versatile platform allows the rapid generation and functional testing of spheroids derived from primary human glioblastoma specimens. To maximize accessibility and ease of integration, we took advantage of commercially available kits to optimize the protocol of spheroid generation we had previously established. This enabled the robust, adaptable, and reproducible formation of homogeneous, multicellular spheroids within a few days. Spheroids generated from one patient specimen were structurally stable and showed a high degree of homogeneity over time. Immunohistochemical and flow cytometric analyses further revealed patient-specific cellular heterogeneity, underscoring the platform's ability to preserve clinically relevant tumor features. Functionally, we demonstrate the applicability of this system for drug response profiling by assessing invasion dynamics following treatment with clinically relevant compounds. Collectively, our results establish a scalable and adaptable 3D screening platform that enables rapid, patient-specific phenotypic and functional analyses. This approach provides a powerful tool to complement existing clinical workflows and holds promise for improving the prediction of therapeutic responses in glioblastoma.

Indexed as

Brain NeoplasmsGlioblastomaSpheroids, CellularHumans3D-culturesbrain tumorsdrug screeningglioblastomainvasion analysismulticellularitypersonalized medicinespheroids

Identifiers

PMID42274613
PMCPMC13256787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.